Lymphoma and myeloma cells are highly sensitive to growth arrest and apoptosis induced by artesunate.

摘要: Objectives The use of new drugs has improved the treatment multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Nevertheless, over time many patients relapse develop resistance to treatment, efforts are needed overcome drug resistance. The widely used malaria artesunate been reported have antitumor activity, we aimed test effects on a panel cells. Methods Myeloma DLBCL cell lines were treated with in vitro. evaluated using ATP content measurements for proliferation annexin V/propidium iodide labeling apoptosis. Western blotting was look artesunate-induced protein changes. In addition, measured patient cells presence bone marrow stromal cells. Results Artesunate efficiently inhibited growth induced apoptosis lines. Apoptosis concomitantly downregulation MYC anti-apoptotic Bcl-2 family proteins, as well cleavage caspase-3. IC50 values varied between 0.3 16.6 μm. Furthermore, some primary also sensitive at doses around 10 μm. Concentrations this order pharmacologically relevant they can be obtained plasma after intravenous administration treatment. Conclusion Our findings indicate that is potential same currently without serious adverse effects.